Type
Business expansion
Country
Slovenia
Region
Slovenija; Osrednjeslovenska;
Location of affected unit(s)
Ljubljana
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.10 - Manufacture of basic pharmaceutical products

120 jobs
Number of planned job creations
Job creation
Announcement Date
29 January 2023
Employment effect (start)
1 March 2023
Foreseen end date
30 September 2024

Description

Pharmaceutical company Lek from Ljubljana, part of the Swiss-based Sandoz group (Novartis), announced an €83 million investment in the Ljubljana plant and the creation of around 120 jobs.

 

The new liquid vial and pre-filled syringe manufacturing facility will be completed in October 2024. In February 2022, the government confirmed the subsidy of €6.56 million for the investment.

 

Novartis intends to spin off the Sandoz division to be sold. Slovenian company Lek is officially part of Sandoz division but produces for both Sandoz and Novartis. It has already been decided that Lek will be divided as well. The units in Ljubljana and Mengeš will be integrated into Novartis, plants in Prevalje and Lendava will stay with Sandoz.

 

According to the Sloexport database, Lek currently employ 4797 workers.


Sources

Citation

Eurofound (2023), Lek, Business expansion in Slovenia, factsheet number 108432, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108432.